Osterweis Capital Management Inc. Purchases 13,169 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Osterweis Capital Management Inc. increased its stake in Thermo Fisher Scientific by 20.5%, acquiring an additional 13,169 shares, bringing its total ownership to 77,455 shares valued at approximately $38.54 million.
• Thermo Fisher Scientific reported earnings of $5.36 per share for the latest quarter, surpassing analysts' expectations of $5.22, and achieved a revenue of $10.86 billion, marking a 2.9% year-over-year increase.
• The company declared a quarterly dividend of $0.43 per share, which will be distributed to shareholders on October 15th, demonstrating a dividend yield of 0.4%.

Osterweis Capital Management Inc. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 20.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,455 shares of the medical research company's stock after purchasing an additional 13,169 shares during the period. Thermo Fisher Scientific comprises about 0.0% of Osterweis Capital Management Inc.'s holdings, making the stock its 22nd largest holding. Osterweis Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $38,542,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $25,000. CBIZ Investment Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares during the period. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $30,000. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth about $30,000. Finally, Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 3.1%

TMO stock opened at $491.29 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The business's 50 day moving average price is $465.84 and its two-hundred day moving average price is $452.06. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $185.52 billion, a price-to-earnings ratio of 28.41, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the business earned $5.37 EPS. The business's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on TMO. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Finally, William Blair initiated coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Seventeen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $592.24.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.